RT Journal Article
T1 Acute myeloid leukaemia of donor cell origin developing 17 years after allogenic hematopoietic cell transplantation for acute promyelocytic leukaemia.
A1 Jiménez, Pilar
A1 Alvarez, J Carlos
A1 Garrido, Pilar
A1 Lorente, J Antonio
A1 Palacios, Jorge
A1 Ruiz-Cabello, Francisco
K1 bone marrow transplantation
K1 donor cell leukaemia
K1 FISH
K1 MLL
K1 STR
K1 Enfermedad Aguda
K1 Trasplante de Médula Ósea
K1 Leucemia promielocítica aguda
K1 Donantes de Tejidos
K1 Femenino
K1 Trasplante de Células Madre Hematopoyéticas
K1 Trasplante Homólogo
AB Donor cell leukaemia (DCL) is a rare complication of allogenic hematopoietic cell transplantation (HCT). We report the case of a female patient with acute promyelocytic leukaemia (APL), FAB type M3, who developed acute myeloid leukaemia (AML) type M5 of donor origin 17 years after allogenic bone marrow transplantation (BMT) from her HLA-matched sister. Morphology and immunophenotyping showed differences with the initial leukaemia, and short tandem repeat (STR) analysis confirmed donor-type haematopoiesis. Interphase fluorescence in situ hybridisation (FISH) showed an 11q23 deletion. Given that the latency period between transplant and development of leukaemia was the longest reported to date, we discuss the mechanisms underlying delayed leukaemia onset.
PB Master Publishing Group
SN 1550-9702
YR 2012
FD 2012-12
LK http://hdl.handle.net/10668/1402
UL http://hdl.handle.net/10668/1402
LA en
NO Jiménez P, Alvarez JC, Garrido P, Lorente JA, Palacios J, Ruiz-Cabello F. Acute myeloid leukaemia of donor cell origin developing 17 years after allogenic hematopoietic cell transplantation for acute promyelocytic leukaemia. Int J Biomed Sci. 2012; 8(4):244-8
NO Journal Article;
DS RISalud
RD Apr 8, 2025